tRF-29-79 regulates lung adenocarcinoma progression through mediating glutamine transporter SLC1A5
Carcinogenesis · 10.06.2024 · 45 (6) · 409-423
DOI: 10.1093/carcin/bgae010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, online erschienen am 15.02.2024. Verfasst von Yuanjian Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Resear…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Polypyrimidine Tract-Binding Protein, Amino Acid Transport System ASC, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Medical Key Laboratory, Jiangsu Provincial Medical Innovation Center.
Abstract (Originalsprache)
In recent decades, considerable evidence has emerged indicating the involvement of tRNA-derived fragments (tRFs) in cancer progression through various mechanisms. However, the biological effects and mechanisms of tRFs in lung adenocarcinoma (LUAD) remain unclear. In this study, we screen out tRF-29-79, a 5ʹ-tRF derived from tRNAGlyGCC, through profiling the tRF expressions in three pairs of LUAD tissues. We show that tRF-29-79 is downregulated in LUAD and downregulation of tRF-29-79 is associated with poorer prognosis. In vivo and in vitro assay reveal that tRF-29-79 inhibits proliferation, migration and invasion of LUAD cells. Mechanistically, we discovered that tRF-29-79 interacts with the RNA-binding protein PTBP1 and facilitates the transportation of PTBP1 from nucleus to cytoplasm, which regulates alternative splicing in the 3ʹ untranslated region (UTR) of SLC1A5 pre-mRNA. Given that SLC1A5 is a core transporter of glutamine, we proved that tRF-29-79 mediate glutamine metabolism of LUAD through affecting the stability of SLC1A5 mRNA, thus exerts its anticancer function. In summary, our findings uncover the novel mechanism that tRF-29-79 participates in glutamine metabolism through interacting with PTBP1 and regulating alternative splicing in the 3ʹ UTR of SLC1A5 pre-mRNA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 42 Baiziting Road, Xuanwu District, Nanjing 210009, China.
- Jiangsu Key Laboratory of Molecular and Translational Cancer Research, 42 Baiziting Road, Xuanwu District, Nanjing 210009, China.
- The Fourth Clinical College of Nanjing Medical University, Nanjing, China.
- The First Clinical College of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Feng Jiang
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Medical Key Laboratory
- Jiangsu Provincial Medical Innovation Center
Zitieren
APA
Shi, Y., Pan, Z., Feng, Y., Zhou, Q., Wang, Q., Wang, H., Dong, G., Xia, W., & Jiang, F. (2024). tRF-29-79 regulates lung adenocarcinoma progression through mediating glutamine transporter SLC1A5. Carcinogenesis, 45(6), 409-423. https://doi.org/10.1093/carcin/bgae010
Vancouver
Shi Y, Pan Z, Feng Y, Zhou Q, Wang Q, Wang H, et al. tRF-29-79 regulates lung adenocarcinoma progression through mediating glutamine transporter SLC1A5. Carcinogenesis. 2024;45(6):409-423. doi:10.1093/carcin/bgae010
BibTeX
@article{Shi2024,
author = {Shi, Yuanjian and Pan, Zehao and Feng, Yipeng and Zhou, Qinyao and Wang, Qinglin and Wang, Hui and Dong, Gaochao and Xia, Wenjie and Jiang, Feng},
title = {tRF-29-79 regulates lung adenocarcinoma progression through mediating glutamine transporter SLC1A5},
journal = {Carcinogenesis},
year = {2024},
volume = {45},
number = {6},
pages = {409--423},
doi = {10.1093/carcin/bgae010}
}
EUVIMED